Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1295027 | 0.86 | ALDH1A1 (0.61) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL2306719 | 0.85 | ALDH1A1 (0.62) | MEN1KMT2ARAB9ANPC1HPGD | |
| SCHEMBL2310023 | 0.84 | ALDH1A1 (0.55) | MEN1KMT2ARAB9ANPC1HPGD | |
| SCHEMBL2062288 | 0.82 | PNMT (0.49) | MEN1KMT2ARAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL17797648 | 0.82 | HPGD (0.51) | MEN1KMT2ARAB9ANPC1HPGD | |
| SCHEMBL3028258 | 0.81 | ALDH1A1 (0.49) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL2061374 | 0.81 | HPGD (0.47) | MEN1KMT2ARAB9ANPC1HPGD | |
| SCHEMBL29052165 | 0.80 | DRD2 (0.46) | ALDH1A1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL25321827 | 0.80 | HTR2C (0.56) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL30475931 | 0.80 | HTR2C (0.56) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022694-B2 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-04 | — | — | US | disclosed |
| US-6972286-B2 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | PHARMACIA AND UPJOHN COMPANY (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1406902-B1 | HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6861420-B2 | N-substituted 1,2,4,5-tetrahydro-1H-benzo[d]azepine compounds | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-23 | — | — | US | disclosed |
| US-20040176609-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1406902-A1 | HEXAHYDROAZEPINO(4,5-G)INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1337530-A1 | OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149024-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-08-07 | — | — | US | disclosed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | disclosed |
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2003006466-A1 | HEXAHYDROAZEPINO (4, 5-G) INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20020133021-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | PHARMACIA & UPJOHN COMPANY | 2002-09-19 | — | — | US | disclosed |
| WO-2002059115-A1 | OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133021-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | MEN1 2504/4885KMT2A 3354/4885RAB9A 3115/4885 |
| US-20030149024-A1 | Therapeutic compounds | REN, HMGCR, RPS4X | MEN1 428/4885KMT2A 4357/4885RAB9A 996/4885 |
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | TPH1, HTR5A, TPH2 | MEN1 655/4885KMT2A 2428/4885RAB9A 1373/4885 |
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | MEN1 2504/4885KMT2A 3354/4885RAB9A 3115/4885 |
| US-20040176609-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | MEN1 2504/4885KMT2A 3354/4885RAB9A 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.